Recognizing Complications
Injection-related complications occur among even the most well-trained providers; recognizing the warning signs is key to preventing long-term damage.

The 2015 International Society of Aesthetic Plastic Surgery (ISAPS) Global Procedural Survey revealed that botulinum toxin injections and hyaluronic acid (HA) dermal fillers are the two most popular nonsurgical procedures, with about 4.6 million toxin and 2.8 million filler treatments performed worldwide. The survey results also showed that HA filler popularity is on the rise, as that number represents...

Articles

Recognizing Complications

The 2015 International Society of Aesthetic Plastic Surgery (ISAPS) Global Procedural...

Rosacea and Systemic Disease

In recent years, researchers have hypothesized that patients with rosacea may be at...

Opening Channels

“The Next Big Thing.” “2016’s Trending Skincare Treatment.” “Our New Favorite Skincare...

Lovely Lips

Lip augmentation is one of the few aesthetic concerns that bridges all age groups....

Products

Professional Peel

The physician-strength ProSystem Retinol Peel from NeoStrata contains 3%...

Cellulite Reducer

The EndyMed Contour handpiece is FDA cleared for temporary reduction in the...

Tinted Sun Protection

EltaMD UV Elements Broad-Spectrum SPF 44 is a 100% physical sunscreen in a...

Easier Aspiration

The Lee Aspirator is a patent-pending safety device that snaps onto cosmetic...

Blogs

Addressing Employee Tardiness
By Paul Edwards, CEO of CEDR HR Solutions There’s nothing more maddening than knowing your patients are due to arrive at your door at any moment, but because one or more of your employees STILL hasn’t shown up for work, you won’t be able to take the patients back right away. Despite the many...
Instagram Stories
By Jasmine Hill, MBA at Aesthetic Influencer Instagram launched their Snapchat-like feature, Instagram Stories this week. The feature lets you share a series of photos or videos (up to 10 seconds) to your followers that will disappear from view in 24 hours. Some aesthetic offices have already...
FDA Calls for More Participation and Diversity in Trials

The U.S. Food and Drug Administration (FDA), which relies heavily on the results from clinical trials, is encouraging more patients to participate in trials—particularly people of all ages, races, ethnic groups and genders—as it will give the Administration a more clear picture of a product’s risks and benefits. The FDA notes that there can be significant differences in how diverse populations respond to medical products, and that information can be added to the label to help doctors and patients make treatment decisions. In addition, trial subjects should be representative of the types of patients who are likely to use the product under investigation.

With this in mind, the FDA issued a release that informs consumers of the importance of clinical trials and the regulations in place to protect them. For example, consumers must remember that if they enroll in a trial to get early access to what they believe is a promising therapy, there are no guarantees that the therapy will work or that they will be assigned to the group of patients who receive it—investigating physicians may not even be aware of some risks until the trials are under way.

To encourage diversity where appropriate, the agency is working with a...

Valeant to Sell Skincare Brands to L’Oréal

Valeant Pharmaceuticals has entered into an agreement to sell its CeraVe, AcneFree and AMBI skincare brands to L’Oréal for $1.3 billion in cash. The CeraVe brand portfolio offers a range of skin care, including cleansers, moisturizers, sunscreens, healing ointments and a dedicated baby line; the AcneFree portfolio offers over-the-counter cleansers and acne treatments; and the AMBI brand portfolio features a range of products formulated for the needs of multicultural consumers that includes creams, cleansers and moisturizers in the face and body category. The product lines have annualized revenue of approximately of $168 million.

Valeant will use the proceeds from the sale to permanently repay term loan debt under its Senior Credit Facility. The transaction is expected to close in the first quarter of 2017, subject to customary closing conditions, including receipt of applicable regulatory approvals.

“We are pleased to announce the progress we are making in reshaping our product portfolio and driving value for our shareholders,” said Valeant CEO Joseph C. Papa. “The success of these products, and today’s transaction, is a testament to the Valeant teams who have impressively grown these brands over the past...

Pierre Fabre Partners With Piqur

Swiss pharmaceutical company Piqur Therapeutics and French pharmaceutical group Pierre Fabre have signed a collaboration agreement for the development of Piqur’s lead compound PQR309, a PI3K/mTOR inhibitor, in dermato-oncology. Piqur and Pierre Fabre’s R&D teams will work together on the evaluation and development of dermatological formulations of PQR309 across multiple therapeutic indications.

Following the first stage of the collaboration, Pierre Fabre will have the option to enter into exclusive negotiations to license global rights for the program in selected skin cancer conditions. Terms and conditions of the collaboration were undisclosed.

“The collaboration with Pierre Fabre, a worldwide leader in dermatology, is an important milestone for Piqur, validating its potential to bring novel solutions to patients for the treatment of dermato-oncology diseases with unmet medical needs,” said Hervé Girsault, chief business officer of Piqur.

“We are looking forward to working with Piqur as part of our commitment to external innovation. This collaboration with Piqur marks an additional milestone in our partnering strategy. Combining our capabilities will accelerate the drug discovery process and bringing...

AAD Commends FDA for Indoor Tanning Restrictions

The American Academy of Dermatology (AAD) applauds the U.S. Food and Drug Administration (FDA) for proposing new regulations governing indoor tanning, including an age restriction for minors under the age of 18 as well as a risk-acknowledgement form that all adults must sign before using indoor tanning devices.


According to the AAD, statistics show that millions of people tan indoors annually and the risk of developing melanoma increases by 59% for individuals exposed to UV radiation from indoor tanning—the risk increases with each use. If the FDA’s proposed rule becomes final,... more »

ASDS Honored With 14 MarCom Awards

The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.


The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.


The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »

Cellfina Available in US

Merz Aesthetics has begun commercial shipment of the Cellfina System, indicated for long-term improvement in the appearance of cellulite in the buttocks and thighs, to aesthetic practices in the U.S.


Cellfina combines proprietary technology with minimally invasive subcision to treat the primary structural cause of dimpled cellulite. Results of the procedure last at least two years—in clinical trials, patient satisfaction with their treatment results improved from 94% at one year to 96% at the two-year mark. The most common side effects reported were soreness, tenderness and bruising... more »